GANGLIOSIDE THERAPY AND GUILLAIN-BARRE-SYNDROME - A HISTORICAL COHORT STUDY IN FERRARA, ITALY, FAILS TO DEMONSTRATE AN ASSOCIATION
GANGLIOSIDE THERAPY AND GUILLAIN-BARRE-SYNDROME - A HISTORICAL COHORT STUDY IN FERRARA, ITALY, FAILS TO DEMONSTRATE AN ASSOCIATION
复制标题
DOI：
10.1159/000110265
复制
发表时间：
1991-07-01
影响因子：
5.7
通讯作者：
ROCCA, WA
中科院分区：
文献类型：
--
作者：
GRANIERI, E;CASETTA, I;ROCCA, WA
我们在一项历史性队列研究中调查了神经节苷脂治疗与发生格林-巴利综合征（GBS）风险之间的所谓关联。 使用意大利北方费拉拉省第31号地方卫生单位的官方医疗记录，我们将1988年1月1日至1990年5月31日期间神经节苷脂的销售数据与住院和出院诊断信息联系起来。 在13，373例接受治疗的受试者队列中，在神经节苷脂给药后30天内观察到的GBS发病病例数（0.0例）与一般人群的预期值（0.014）无显著差异。 我们的研究表明，接受神经节苷脂的患者发生GBS的风险并没有增加。 然而，由于样本量的限制，这些发现应该在更大的队列研究中得到证实。
We investigated an alleged association between ganglioside therapy and the risk of developing the Guillain-Barre syndrome (GBS) in a historical cohort study. Using official medical records of the Local Health Unit No. 31 of Ferrara Province, northern Italy, we linked data on sales of gangliosides with information regarding hospital admissions and discharge diagnoses between January 1, 1988, and May 31, 1990. The number of incidence cases of GBS observed within 30 days of gangliosides administration in a cohort of 13,373 treated subjects (0.0 cases) was not significantly different from that expected in the general population (0.014). Our study suggests that patients receiving gangliosides are not at increased risk of developing GBS. However, because of sample size limitations, these findings should be confirmed in a larger cohort study.